Добавил:
Sekretar
kiopkiopkiop18@yandex.ru
t.me/Prokururor I Вовсе не секретарь, но почту проверяю
Опубликованный материал нарушает ваши авторские права? Сообщите нам.
Вуз:
Предмет:
Файл:Ординатура / Хирургия / Библиотека им академика М.И. Перельмана / Книга_5224_Библиотеки_им_академика_М_И_Перельмана.pdf
X
- •Contents
- •Outcome Evaluation
- •Introduction
- •Clinical Presentation of Muscular Weakness in the Critical Patients
- •Critical Illness Polyneuropathy (CIP) and Critical Illness Myopathy (CIM)
- •Ventilator-Induced Diaphragmatic Dysfunction (VIDD)
- •Dysphagia, Swallowing, and Effective Cough
- •The Pathophysiology of Acute Skeletal Muscle Wasting
- •Risk Factors
- •Short-Term and Long-Term Outcome
- •Conclusions
- •References
- •Introduction
- •The Neuroendocrine Response
- •Pathophysiology of Stress Response
- •The Hypothalamus-Pituitary-Adrenal (HPA) Axis
- •GH Axis
- •Pituitary-Thyroid Axis
- •Pituitary-Adrenal Axis
- •Mitochondrial Dysfunction
- •Metabolic Aspects of Stress Response
- •Conclusion
- •References
- •Introduction
- •Disorders of Fluid Balance
- •Dysionemias
- •Dysnatremias
- •Dyskalemias
- •Other Electrolyte Derangements (Calcium, Magnesium, Phosphorus)
- •Alterations of Acid Base Balance
- •Acid-Base Disturbances
- •Metabolic Acidosis
- •Respiratory Acidosis
- •Metabolic Alkalosis
- •Respiratory Alkalosis
- •Conclusion
- •References
- •Introduction
- •Epidemiology and Risk Factors
- •Diagnosis
- •Differential Diagnosis
- •Treatment
- •Prognosis
- •Future Perspectives
- •References
- •Introduction
- •Gut Microbiome
- •Gut-Organ Axis
- •Gut-Lung Axis
- •ICU Dysbiosis
- •Gut Changes
- •Microbial Therapy in ICU
- •Antimicrobial Stewardship
- •Nutrition as a Key Factor for Gut Microbiome Homeostasis
- •Probiotics, Prebiotics, and Synbiotics
- •Fecal Microbiota Transplantation
- •Conclusion
- •References
- •Introduction
- •Validation Process
- •Screening Tools Overview
- •Discussion
- •Conclusion
- •References
- •Introduction
- •Fight-and-Flight Reaction
- •Calorimetry and Total Energy Expenditure
- •Role of Mitochondria in the Various Stages of Intensive Care Recovery
- •REE in Different Clinical Scenarios
- •Conclusions
- •References
- •Introduction
- •Nutrition in ICU: Evidence from RCTs
- •Inclusion of Too Many Patients Considered at Low Nutritional Risk
- •Unfavorable Energy to Protein Doses
- •Absence of Indirect Calorimetry-Guided Energy Dosing
- •Anabolic Resistance
- •Suppression of Fasting-Induced Recovery Pathways
- •Future Perspectives
- •Development and Validation of Tools to Guide Individualized Nutritional Support
- •Implications for Clinical Practice
- •Conclusion
- •References
- •Introduction
- •Protein Metabolism in Critical Illness
- •Protein Requirements and Current Evidence
- •Timing of Introduction
- •Early mobilization, Exercise, and Adjuvant Therapies
- •Conclusion
- •References
- •Introduction
- •Computed Tomography Scan
- •Bioelectrical Impedance Analysis
- •Musculoskeletal Ultrasound
- •Respiratory Muscle Ultrasound
- •Limb Muscles
- •Conclusions
- •References
- •Functional Principles
- •Hydration Status Evaluations in Critically Ill Patients
- •Body Composition and Nutrition in ICU
- •Limits of BIVA in Critically Ill Patients
- •Conclusions
- •References
- •Introduction
- •Introduction
- •Historical Perspective
- •Enteral Versus Parenteral Nutrition Nowadays
- •Conclusions
- •References
- •Enteral Nutrition
- •Components of Enteral Mixtures
- •Choice of the Enteral Mixture
- •Special Composition Formulas
- •Conclusions
- •References
- •Introduction
- •Complications Related to Enteral Feeding Tubes
- •Aspiration
- •Gastrointestinal Intolerance
- •Diarrhea
- •New Horizons
- •New Technologies to Prevent Enteral Nutrition Complications
- •Advanced Tube Feedings
- •smART Platform
- •Conclusions
- •References
- •Introduction
- •Composition of PN Admixtures
- •Energetic Substrates
- •Carbohydrates
- •Lipid Emulsions
- •Proteins
- •Micronutrients: Electrolytes, Vitamins, and Trace Elements
- •Types of Parenteral Nutrition
- •Compatibility and Stability of the Parenteral Nutrition
- •References
- •Introduction
- •Metabolic Complications
- •Hyperglycemia
- •Hypertriglyceridemia
- •Liver Disease: Steatosis, Cholestatic Disease, and Gallbladder Stones
- •Refeeding Syndrome
- •Mechanical Complications
- •Infectious Complications
- •Conclusions
- •References
- •Introduction
- •Macronutrients
- •Glutamine
- •Arginine
- •Leucine
- •ω-3 Fatty Acids
- •Micronutrients
- •Antioxidant Vitamins
- •Antioxidant Trace Elements
- •Probiotics, Prebiotics or Symbiotics
- •Use of Probiotics in Clinical Practice?
- •References
- •Introduction
- •Pathophysiological Mechanisms, Risk Factors, and Clinical Implications
- •Pathophysiological Mechanisms of ICUAW
- •Risk Factors Associated with Physical and Functional Recovery in Critically Ill Patients
- •Clinical Impact of Poor Physical and Functional Recovery in Critical Illnesses
- •How to Assess Physical and Functional Recovery in Critical Illnesses
- •Management and Therapies
- •Nutritional Therapy
- •Other Supportive Therapies
- •Patient- and Family-centered ICU Environment
- •Conclusions
- •References
- •Bioethics in Clinical Practices
- •Ethical Consideration on Nutrition
- •Conclusion
- •References
- •Introduction
- •Nutrition in ARDS
- •Caloric Goals
- •Diet Composition
- •Immunonutrition
- •Oral Versus Enteral Versus Parenteral Nutrition
- •Nutrition in COVID-19 Respiratory Failure
- •Nutrition in ECMO Support
- •Enteral Nutrition
- •Parenteral Nutrition
- •Nutritional Goals
- •Conclusions
- •References
- •Introduction
- •Timing and Route of Nutritional Support
- •Initial Assessment of the Burn Patient
- •Estimation of Energy Expenditure
- •Macronutrients and Micronutrients
- •Proteins
- •Carbohydrates
- •Immunonutrients
- •Arginine
- •Nucleotides
- •ω3 Fatty Acids
- •Glutamine
- •Monitoring of Nutritional Support
- •Nutritional Support for Trauma Patients
- •Route of Feeding: Digestive Tract (Enteral Nutrition) Versus Intravenous (Parenteral Nutrition)
- •Standard or Immune-Enhancing Enteral Nutrition
- •Estimation or Measurement of Energy Requirements
- •Macronutrients
- •Conclusions
- •References
- •Introduction
- •General Considerations
- •Assessment of Nutritional Needs
- •Metabolic Changes Induced by Sepsis, AKI, and CRRT
- •Protein Metabolism
- •Lipid Metabolism
- •Vitamins and Trace Elements
- •Phosphates
- •Approaches to Nutrition
- •Enteral
- •Parenteral
- •Timing
- •Recommendations
- •Conclusion
- •References
- •Introduction
- •Acute Liver Failure
- •Nutrition in ALF
- •Acute Pancreatitis
- •IAP Management
- •Conclusions
- •References
- •Introduction
- •Nutritional Considerations in Major Surgery
- •Nutritional Requirements During and After Major Surgery
- •Challenges in Meeting Nutritional Needs Post-Surgery
- •Strategies for Enhancing Nutritional Intake and Absorption
- •Intestinal Failure: Nutritional Challenges and Management
- •Impact of Intestinal Failure on Nutritional Status
- •Nutritional Management Strategies for Patients with Intestinal Failure
- •Role of Parenteral Nutrition and Enteral Nutrition in Intestinal Failure Cases
- •Open Abdomen: Nutritional Support and Wound Healing
- •Nutritional Requirements for Patients with Open Abdomen Wounds
- •Challenges in Providing Nutritional Support to Patients with Open Abdomen
- •Clinical Protocols and Guidelines for Nutritional Support
- •Conclusions
- •References
- •Introduction
- •Nutrition Therapy
- •Determination of Energy Expenditure
- •Route and Timing of Enteral Nutrition
- •Intolerance to Enteral Nutrition
- •Brain Energy Metabolism and Energy Dysfunction Following Acute Brain Injury
- •In Vivo Brain Energy and Glucose Monitoring
- •Alternative Energy Substrates
- •Lactate
- •Ketone Bodies
- •Immunonutrition and Micronutrients
- •Conclusions and Future Directions
- •References
- •Introduction
- •AKI and Cardiac Surgery
- •AKI and Vascular Surgery
- •AKI and Sepsis
- •AKI and Surgery
- •Trauma
- •Burn
- •AKI and COVID-19
- •Conclusion
- •References
- •Introduction
- •AKI Etiology
- •Subclinical AKI and AKI Biomarkers
- •Subphenotyping AKI
- •Conclusions
- •References
- •Introduction
- •What Are Biomarkers?
- •Novel Biomarkers: How Can They be Implemented?
- •Biomarkers for the Prediction of AKI and Detection of Subclinical Stages
- •Postoperative Biomarker-Guided Prevention of AKI in Patients at High Risk
- •Biomarkers for Other Indications
- •Conclusion
- •References
- •Introduction
- •The Machine Learning Arena
- •The Challenges of Timely Prediction of Acute Kidney Injury
- •Early Machine Learning Models for AKI Prediction
- •New Techniques for AKI Prediction Using Deep Learning ML Models
- •Clinical Decision Support Systems
- •The Translational Research Gap and the Value of Data Sharing: A Plea for Data Sharing
- •Limitations of Machine Learning Models
- •Conclusions
- •References
- •Introduction
- •Doppler Assesses Vascular Congestion
- •Arterial Renal Doppler Ultrasound in AKI
- •Integration of Renal Resistive Index and Intrarenal Venous Flow
- •Contrast-Enhanced Ultrasound for Assessing Renal Perfusion
- •Conclusions
- •References
- •Introduction
- •Renal Perfusion and Goals of Fluids in AKI
- •Clinical Evaluation of a Patient with AKI in ICU
- •Studies Which Investigated the Association of Fluid Therapy and AKI
- •Volume of Fluid
- •Type of Fluid
- •Crystalloids
- •Colloids
- •Starches
- •Gelatins
- •Conclusion
- •References
- •Introduction
- •Pathophysiology of Renal Perfusion
- •Acute Kidney Injury
- •Norepinephrine
- •Epinephrine
- •Dopamine
- •Vasopressin
- •Terlipressin
- •Angiotensin II
- •Conclusions
- •References
- •Introduction
- •Pharmacology of Diuretics
- •Loop Diuretics
- •Other Classes of Diuretics
- •Indications for Diuretics in AKI
- •Control of Fluid Overload
- •AKI Prognostication
- •Situations in Which Diuretics Are Not Indicated
- •AKI Recovery
- •How to Use Diuretics in the ICU
- •Class and Dose Selection
- •Modality of Loop Diuretic Administration
- •Conclusions
- •References
- •Introduction
- •What Is Acute Kidney Disease?
- •Clinical Course of AKD Within the ICU
- •Management of AKD in Critical Care and Beyond
- •Conclusions and Future Directions
- •References
- •Introduction
- •Renal Functional Reserve
- •Renal Functional Reserve and Renal Recovery After Acute Kidney Injury
- •Conclusion
- •References
- •Background
- •Membrane and Filter Characteristics
- •Geometric Characteristics
- •Performance Characteristics
- •Mechanisms of Fluid and Solute Transport
- •Treatment Modalities
- •Treatment Dose
- •Nomenclature of Renal Replacement Therapies
- •Continuous Therapies
- •Intermittent Therapies
- •Hybrid Therapies
- •Conclusion
- •References
- •Introduction
- •Dialysis Catheters: Technical Aspects
- •Selection of the Site for Dialysis
- •Catheter Insertion Technique
- •Dialysis Catheter Complications
- •Dialysis Catheter Maintenance
- •Conclusions
- •References
- •Introduction
- •Non-pharmacological Strategies to Reduce Membrane Fouling
- •Pharmacological Strategies to Reduce Membrane Clotting
- •Unfractionated Heparin (UFH) Systemic Anticoagulation
- •Systemic Anticoagulation with Low Molecular Weight Heparin (LMWH)
- •Regional Citrate Anticoagulation (RCA)
- •Systemic Anticoagulation with Direct Thrombin Antagonists
- •Nafamostat
- •Conclusions
- •References
- •Introduction
- •CRRT Dose/Outcome Studies: Consideration of Solute Kinetics
- •CRRT Dose as a Quality Criterion
- •CRRT Dose in the Context of Therapy Quality
- •Conclusions
- •References
- •Introduction
- •Patient Selection and Indications for Starting RRT
- •Strategies to Identify Need for RRT
- •Rationale for an Early Strategy to Starting RRT
- •Rationale for a Conservative Strategy to Starting RRT
- •RRT Replacement Therapy and Clinical Outcomes
- •Current Clinical Practice Guideline Recommendations
- •Clinical Trial Evidence on Timing of Starting RRT
- •Implications for Practice
- •Existing Knowledge Gaps and Future Research
- •Conclusions
- •References
- •Introduction
- •Early ICU Phase before KRT
- •Nutrition Care
- •Monitoring
- •ICU Phase with KRT
- •Gains and Losses During CRRT
- •Electrolyte Loss in CRRT
- •Macronutrient Loss in CRRT
- •Macronutrient Gain in CRRT
- •Micronutrients and Vitamin Loss in CRRT
- •Management of Losses During CRRT
- •Monitoring During CRRT
- •Indirect Calorimetry During CRRT
- •ICU Phase After CRRT
- •EN and PN Product Selection
- •Conclusions
- •References
- •Introduction
- •Nomenclature
- •Continuous Therapies
- •Intermittent Renal Replacement Therapies (IRRTs)
- •Hybrid Therapies
- •Technical Aspects of RRT Techniques
- •Hemodynamic Stability
- •Solute Clearance
- •Fluid Balance
- •Vascular Access
- •Anticoagulation
- •Drug Dosing
- •Patient Mobilization
- •The Process of RRT Prescription and Administration
- •Indications of RRT
- •Timing
- •Prescription Parameters
- •Dosing
- •Membrane Choice
- •Dialysate and Reinfusion Solutions
- •Limitations of RRT in Critical Care
- •Patient Safety During RRT in Critical Care
- •Introduction
- •Steps in RRT Management and Protocol Application

336 T. von Groote et al.
understanding and utilization of AKI biomarkers. Embracing these advancements
heralds a shift toward precision medicine and more effective AKI care pathways.
References
1. Biomarkers Definitions Working Group. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther. 2001;69:89–95.
1067/mcp.2001.113989.
2. Ostermann M, Zarbock A, Goldstein S, Kashani K, Macedo E, Murugan R, Bell M, Forni L,
Guzzi L, Joannidis M, Kane-Gill SL, Legrand M, Mehta R, Murray PT, Pickkers P, Plebani M,
Prowle J, Ricci Z, Rimmelé T, Rosner M, Shaw AD, Kellum JA, Ronco C. Recommendations
on acute kidney injury biomarkers from the acute Disease quality initiative consensus conference: a consensus statement. JAMA Netw Open. 2020;3:e2019209. https://doi.org/10.1001/
jamanetworkopen.2020.19209.
3. Kidney Disease: Improving global outcomes (KDIGO) acute kidney injury work group.
KDIGO clinical practice guideline for acute kidney injury. Kidney Int Suppl. 2012;2:1–138.
4. Khwaja A. KDIGO clinical practice guidelines for acute kidney injury. Nephron Clin Pract.
2012;120:c179–84. https://doi.org/10.1159/000339789.
5. Schetz M, Schortgen F. Ten shortcomings of the current definition of AKI. Intensive Care Med.
2017;43:911–3. https://doi.org/10.1007/s00134-017-4715-2.
6. Molitoris BA, Reilly E. Quantifying glomerular filtration rates in acute kidney injury: a
requirement for translational success. Semin Nephrol. 2016;36:31–41. https://doi.org/10.
1016/j.semnephrol.2016.01.008.
7. Schetz M, Gunst J, Van den Berghe G. The impact of using estimated GFR versus creatinine
clearance on the evaluation of recovery from acute kidney injury in the ICU. Intensive Care
Med. 2014;40:1709–17. https://doi.org/10.1007/s00134-014-3487-1.
8. Shlipak MG, Inker LA, Coresh J. Serum cystatin C for estimation of GFR. JAMA. 2022;328:
883–4. https://doi.org/10.1001/jama.2022.12407.
9. Adingwupu OM, Barbosa ER, Palevsky PM, Vassalotti JA, Levey AS, Inker LA. Cystatin C as
a GFR estimation marker in acute and chronic illness: a systematic review. Kidney Med.
2023;5:100727. https://doi.org/10.1016/j.xkme.2023.10072.
10. von Groote T, Meersch-Dini M. Biomarkers for the prediction and judgement of sepsis and
sepsis complications: a step towards precision medicine? J Clin Med. 2022;11:5782. https://doi.
org/10.3390/jcm11195782.
11. Porschen C, Strauss C, Meersch M, Zarbock A. Personalized acute kidney injury treatment.
Curr Opin Crit Care. 2023;29:551. https://doi.org/10.1097/MCC.0000000000001089.
12. Koyner JL, Zarbock A, Basu RK, Ronco C. The impact of biomarkers of acute kidney injury on
individual patient care. Nephrol Dial Transplant. 2019;35:1295–305. https://doi.org/10.1093/
ndt/gfz188.
13. Kane-Gill SL, Meersch M, Bell M. Biomarker-guided management of acute kidney injury. Curr
Opin Crit Care. 2020;26:556–62. https://doi.org/10.1097/MCC.0000000000000777.
14. Hoste E, Bihorac A, Al-Khafaji A, Ortega LM, Ostermann M, Haase M, Zacharowski K,
Wunderink R, Heung M, Lissauer M, Self WH, Koyner JL, Honore PM, Prowle JR,
Joannidis M, Forni LG, Kampf JP, McPherson P, Kellum JA, Chawla LS. Identification and
validation of biomarkers of persistent acute kidney injury: the RUBY study. Intensive Care
Med. 2020;46:943–53. https://doi.org/10.1007/s00134-019-05919-0. Epub 2020 Feb 6. PMID:
32025755; PMCID: PMC7210248.
15.
Meersch M,
von Groote T, Zarbock A. Predicting the development of renal replacement therapy indications
by combining the furosemide stress test and chemokine (C-C motif) ligand 14 in a cohort of
Weiss R, Gerss J, Albert F, Gruber J, Kellum JA, Chawla L, Forni LG, Koyner JL,
https://doi.org/10.

28 Biomarkers for Acute Kidney Injury 337
postsurgical patients. Crit Care Med. 2023;51:1033–42. https ://doi.org/10.1097/C CM.
0000000000005849.
16. Katulka RJ, Al Saadon A,
RTN, Bagshaw SM, Rewa OG. Determining the optimal time for liberation from renal
replacement therapy in critically ill patients: a systematic review and meta-analysis (DOnE
RRT). Crit Care. 2020;24:50. https://doi.org/10.1186/s13054-020-2751-8. PMID: 32054522;
PMCID: PMC7020497.
17. Uchino S, Bellomo R, Morimatsu H, Morgera S, Schetz M, Tan I, Bouman C, Macedo E,
Gibney N, Tolwani A, Straaten HO, Ronco C, Kellum JA. Discontinuation of continuous renal
replacement therapy: a post hoc analysis of a prospective multicenter observational study*. Crit
Care Med. 2009;37:2576. https://doi.org/10.1097/CCM.0b013e3181a38241.
18. Haase M, Devarajan P, Haase-Fielitz A, Bellomo R, Cruz DN, Wagener G, Krawczeski CD,
Koyner JL, Murray P, Zappitelli M, Goldstein SL, Makris K, Ronco C, Martensson J, Martling
CR, Venge P, Siew E, Ware LB, Ikizler TA, Mertens PR. The outcome of neutrophil gelatinaseassociated lipocalin-positive subclinical acute kidney injury: a multicenter pooled analysis of
prospective studies. J Am Coll Cardiol. 2011;57(17):1752–61. https://doi.org/10.1016/j.jacc.
2010.11.051. PMID: 21511111; PMCID: PMC4866647.
19. Chawla LS, Bellomo R, Bihorac A, Goldstein SL, Siew ED, Bagshaw SM, Bittleman D,
Cruz D, Endre Z, Fitzgerald RL, Forni L, Kane-Gill SL, Hoste E, Koyner J, Liu KD,
Macedo E, Mehta R, Murray P, Nadim M, Ostermann M, Palevsky PM, Pannu N, Rosner M,
Wald R, Zarbock A, Ronco C, Kellum JA. Acute disease quality initiative workgroup 16. Acute
kidney disease and renal recovery: consensus report of the Acute Disease Quality Initiative
(ADQI) 16 Workgroup. Nat Rev Nephrol. 2017;13(4):241 – 57.
2017.2. Epub 2017 Feb 27.
20. Kashani K, Al-Khafaji A, Ardiles T, Artigas A, Bagshaw SM, Bell M, Bihorac A, Birkhahn R,
Cely CM, Chawla LS, Davison DL, Feldkamp T, Forni LG, Gong MN, Gunnerson KJ,
Haase M, Hackett J, Honore PM, Hoste EA, Joannes-Boyau O, Joannidis M, Kim P, Koyner
JL, Laskowitz DT, Lissauer ME, Marx G, McCullough PA, Mullaney S, Ostermann M,
Rimmelé T, Shapiro NI, Shaw AD, Shi J, Sprague AM, Vincent JL, Vinsonneau C,
Wagner L, Walker MG, Wilkerson RG, Zacharowski K, Kellum JA. Discovery and validation
of cell cycle arrest biomarkers in human acute kidney injury. Crit Care. 2013;17(1):R25. https://
doi.org/10.1186/cc12503. PMID: 23388612; PMCID: PMC4057242.
21. Han WK, Bailly V, Abichandani R, Thadhani R, Bonventre JV. Kidney injury Molecule-1
(KIM-1): a novel biomarker for human renal proximal tubule injury. Kidney Int. 2002 Jul;62(1):
237–44. https://doi.org/10.1046/j.1523-1755.2002.00433.x.
22. Meersch M, Schmidt C, Hoffmeier A, Van Aken H, Wempe C, Gerss J, Zarbock A. Prevention
of cardiac surgery-associated AKI by implementing the KDIGO guidelines in high risk patients
identified by biomarkers: the PrevAKI randomized controlled trial. Intensive Care Med.
2017;43(11):1551–61. https://doi.org/10.1007/s00134-016-4670-3. Epub 2017 Jan 21.
Erratum in: Intensive Care Med. 2017 Mar 7; PMID: 28110412; PMCID: PMC5633630.
23. Zarbock A, Küllmar M, Ostermann M, Lucchese G, Baig K, Cennamo A, Rajani R,
McCorkell S, Arndt C, Wulf H, Irqsusi M, Monaco F, Di Prima AL, García Alvarez M,
Italiano S, Miralles Bagan J, Kunst G, Nair S, L’Acqua C, Hoste E, Vandenberghe W, Honore
PM, Kellum JA, Forni LG, Grieshaber P, Massoth C, Weiss R, Gerss J, Wempe C, Meersch
M. Prevention of cardiac surgery-associated acute kidney injury by implementing the KDIGO
guidelines in high-risk patients identified by biomarkers: the PrevAKI-multicenter randomized
controlled trial. Anesth Analg. 2021;133(2):292–302. https://doi.org/10.1213/ANE.
0000000000005458
24.
Göcze I,
Banas B, Bein T, Schlitt HJ, Bergler T. Biomarker-guided intervention to prevent acute kidney
injury after major surgery: the prospective randomized BigpAK study. Ann Surg. 2018 Jun;267
(6):1013–20. https://doi.org/10.1097/SLA.0000000000002485.
Jauch D, Götz M, Kennedy P, Jung B, Zeman F, Gnewuch C, Graf BM, Gnann W,
Sebastianski M, Featherstone R, Vandermeer B, Silver SA, Gibney
https://doi.org/10.1038/nrneph.
.

338 T. von Groote et al.
25. Vaidya VS, Waikar SS, Ferguson MA, Collings FB, Sunderland K, Gioules C, Bradwin G,
Matsouaka R, Betensky RA, Curhan GC, Bonventre JV. Urinary biomarkers for sensitive and
specific detection of acute kidney injury in humans. Clin Transl Sci. 2008;1(3):200–8. https://
doi.org/10.1111/j.1752-8062.2008.00053.x. PMID: 19212447; PMCID: PMC2638059.
26. Koyner JL, Vaidya VS, Bennett MR, Ma Q, Worcester E, Akhter SA, Raman J,
Jeevanandam V, O’Connor MF, Devarajan P, Bonventre JV, Murray PT. Urinary biomarkers
in the clinical prognosis and early detection of acute kidney injury. Clin J Am Soc Nephrol.
2010;5(12):2154–65. https://doi.org/10.2215/CJN.00740110. Epub 2010 Aug 26. PMID:
20798258; PMCID: PMC2994075.
27. Koyner JL, Garg AX, Coca SG, Sint K, Thiessen-Philbrook H, Patel UD, Shlipak MG, Parikh
CR. TRIBE-AKI Consortium. Biomarkers predict progression of acute kidney injury after
cardiac surger y. J Am Soc Nephrol. 2012;23(5):905–14. https://doi.org/10.1681/ASN.
2011090907. Epub 2012 Mar 1. Erratum in: J Am Soc Nephrol. 2012 Jul;23(7):1271. PMID:
22383693; PMCID: PMC3338298.
28. Griffin BR, Gist KM, Faubel S. Current status of novel biomarkers for the diagnosis of acute
kidney injury: a historical perspective. J Intensive Care Med. 2020;35(5):415–24. https://doi.
org/10.1177/0885066618824531. Epub 2019 Jan 17. PMID: 30654681; PMCID:
PMC7333543.
29. Zarbock A, Weiss R, Albert F, Rutledge K, Kellum JA, Bellomo R, Grigoryev E, Candela-Toha
AM, Demir ZA, Legros V, Rosenberger P, Galán Menéndez P, Garcia Alvarez M, Peng K,
Léger M, Khalel W, Orhan-Sungur M, Meersch M, The EPIS-AKI Investigators. Epidemiology
of surgery associated acute kidney injury (EPIS-AKI): a prospective international observational
multi-center clinical study. Intensive Care Med. 2023;49(12):1441–55.
s00134-023-07169-7. Epub 2023 Jul 28. PMID: 37505258; PMCID: PMC10709241.
30. Poukkanen M, Vaara ST, Pettilä V, Kaukonen KM, Korhonen AM, Hovilehto S, Inkinen O,
Laru-Sompa R, Kaminski T, Reinikainen M, Lund V, Karlsson S, FINNAKI study group.
Acute kidney injury in patients with severe sepsis in Finnish intensive care units. Acta
Anaesthesiol Scand. 2013;57(7):863–72. https://doi.org/10.1111/aas.12133. Epub
2013 May 28
31. Pickkers P, Darmon M, Hoste E, Joannidis M, Legrand M, Ostermann M, Prowle JR,
Schneider A, Schetz M. Acute kidney injury in the critically ill: an updated review on
pathophysiology and management. Intensive Care Med. 2021;47(8):835–50. https://doi.org/
10.1007/s00134-021-06454-7. Epub 2021 Jul 2. PMID: 34213593; PMCID: PMC8249842.
32. Glassford NJ, Schneider AG, Xu S, Eastwood GM, Young H, Peck L, Venge P, Bellomo R. The
nature and discriminatory value of urinary neutrophil gelatinase-associated lipocalin in critically
ill patients at risk of acute kidney injury. Intensive Care Med. 2013;39(10):1714–24. https://doi.
org/10.1007/s00134-013-3040-7. Epub 2013 Aug 6
33. von Groote T, Albert F, Meersch M, Koch R, Porschen C, Hartmann O, Bergmann D,
Pickkers P, Zarbock A. Proenkephalin a 119-159 predicts early and successful liberation from
renal replacement therapy in critically ill patients with acute kidney injury: a post hoc analysis
of the ELAIN trial. Crit Care. 2022;26(1):333. https://doi.org/10.1186/s13054-022-
04217-4. PMID: 36316692; PMCID: PMC9624047.
34. von Groote T, Albert F, Meersch M, Koch R, Gerss J, Arlt B, Sadjadi M, Porschen C,
Pickkers P, Zarbock A, RICH investigators. Evaluation of Proenkephalin a 119-159 for
liberation from renal replacement therapy: an external, multicenter pilot study in critically ill
patients with acute kidney injury. Crit Care. 2023;(1):27, 276. https://doi.org/10.1186/s13054-
023-04556-w. PMID: 37430375; PMCID: PMC10332055.
35.
Schunk SJ,
Wagenpfeil S, Gröne HJ, Schäfers HJ, Fliser D, Speer T, Zewinger S. Association between
urinary dickkopf-3, acute kidney injury, and subsequent loss of kidney function in patients
undergoing cardiac surgery: an observational cohort study. Lancet. 2019;394(10197):488–96.
https://doi.org/10.1016/S0140-6736(19)30769-X. Epub 2019 Jun 12
Zarbock A, Meersch M, Küllmar M, Kellum JA, Schmit D, Wagner M, Triem S,
https://doi.org/10.1007/

28 Biomarkers for Acute Kidney Injury 339
36. Sánchez-Álamo B, García-Iñigo FJ, Shabaka A, Acedo JM, Cases-Corona C, DomínguezTorres P, Diaz-Enamorado Y, Landaluce E, Navarro-González JF, Gorriz JL, MartínezCastelao A, Fernández-Juárez G. Urinary Dickkopf-3: a new biomarker for CKD progression
and mortality. Nephrol Dial Transplant. 2021;36(12):2199–207. https://doi.org/10.1093/ndt/
gfab198.
37. Roscigno G, Quintavalle C, Biondi-Zoccai G, De Micco F, Frati G, Affinito A, Nuzzo S,
Condorelli G, Briguori C. Urinary Dickkopf-3 and contrast-associated kidney damage. J Am
Coll Cardiol. 2021;77(21):2667–76. https://doi.org/10.1016/j.jacc.2021.03.330.
38. Reddy K, Sinha P, O’Kane CM, Gordon AC, Calfee CS, McAuley DF. Subphenotypes in
critical care: translation into clinical practice. Lancet Respir Med. 2020;8(6):631–43. https://
doi.org/10.1016/S2213-2600(20)30124-7.
39. Bhatraju PK, Zelnick LR, Herting J, Katz R, Mikacenic C, Kosamo S, Morrell ED, RobinsonCohen C, Calfee CS, Christie JD, Liu KD, Matthay MA, Hahn WO, Dmyterko V, Slivinski
NSJ, Russell JA, Walley KR, Christiani DC, Liles WC, Himmelfarb J, Wurfel
MM. Identification of acute kidney injury subphenotypes with differing molecular signatures
and responses to vasopressin therapy. Am J Respir Crit Care Med. 2019;199(7):863–72. https://
doi.org/10.1164/rccm.201807-1346OC. PMID: 30334632; PMCID: PMC6444649.
40. Kellum JA, Sileanu FE, Bihorac A, Hoste EA, Chawla LS. Recovery after acute kidney injury.
Am J Respir Crit Care Med. 2017;195(6):784–91. https://doi.org/10.1164/rccm.201604-
0799OC. PMID: 27635668; PMCID: PMC5363967.
Devarajan P.
41.
Review: neutrophil gelatinase-associated lipocalin: a troponin-like biomarker for
human acute kidney injury. Nephrology (Carlton). 2010 Jun;15(4):419–28. https://doi.org/10.
1111/j.1440-1797.2010.01317.x.

Chapter 29
Prediction and Machine Learning Models
for Early Prediction of AKI
Massimiliano Greco, Ilesa Bose, and Giovanni Angelotti
Introduction
In the realm of critical care medicine, the integration of cutting-edge technologies
has revolutionized patient care and clinical workflows. Among these technologies,
machine learning (ML) stands as a transformative tool, offering unparalleled opportunities for predictive analytics and personalized patient management. This chapter
explores the intersection of machine learning and critical care, with a specific focus
on its role in predicting acute kidney injury (AKI). AKI poses significant challenges
in critical care, with traditional diagnostic criteria often lacking in capturing subtle
renal dysfunction. Recognizing this gap, researchers and clinicians have turned to
machine learning algorithms to enhance early detection and intervention. ML
empowers algorithms to analyze diverse clinical datasets, identify patterns, and
generate predictive models without explicit programming, thus facilitating timely
intervention and AKI management. Throughout this chapter, we examine key
studies and innovative approaches in machine learning-based AKI prediction.
Supplementary Information The online version contains supplementary material available at
https://doi.org/10.1007/978-3-031-66541-7_29.
M. Greco (
Department of Biomedical Sciences, Humanitas University, Milan, Italy
IRCCS Humanitas Research Hospital, Milan, Italy
e-mail: massimiliano.greco@hunimed.eu
I. Bose
Department
e-mail: ilesa.bose@st.hunimed.eu
G. Angelotti
IRCCS
e-mail: giovanni.angelotti@humanitas.it
© The
A. Cotoia et al. (eds.), Nutrition, Metabolism and Kidney Support,
https://doi.org/10.1007/978-3-031-66541-7_29
✉)
of Biomedical Sciences, Humanitas University, Milan, Italy
Humanitas Research Hospital, Milan, Italy
Author(s), under exclusive license to Springer Nature Switzerland AG 2024
341

342 M. Greco et al.
From early models using random forest algorithms to advanced deep learning
techniques leveraging extensive datasets, ML in critical care promises precision
medicine and personalized patient care. Furthermore, we explore the integration of
machine learning models into clinical decision support systems (CDSS), highlighting their role in providing clinicians with timely alerts and personalized recommendations at the point of care. By seamlessly integrating p
empower clinicians to make informed decisions and optimize patient outcomes. As
we navigate the complexities of machine learning in critical care, it is crucial to
address challenges such as data interoperability, model validation, and ethical
considerations. Achieving seamless integration into clinical practice requires collaborative efforts from researchers, clinicians, and policymakers. This chapter examines
both the opportu
learning to improve patient care in critical settings.
nities and obstacles in harnessing the full potential of machine
redictive analytics, CDSS
The Machine Learning Arena
In recent years, artificial intelligence (AI) has been revolutionizing our lives, with the
proliferation of self-driving vehicles, image or video generators, and large language
models. It is also gaining a prominent role in medicine and critical care [1]. Machine
learning (ML), a subclass of artificial intelligence, utilizes algorithms designed to
learn and adapt to various types and patterns of data autonomously, without being
explicitly programmed. Machine learning models range from the earliest techniques
of automatic feature selection in linear and logistic regression to supervised models
such as random forests or gradient boosting and to advanced deep learning models
[2]. ML models hold significant potential to enhance the quality of care, increase the
cost-effectiveness of interventions, and propel the field of medicine toward precision
medicine [
published research models and their real-world applications in ML, a challenge
that has yet to be addressed [4].
3]. However, a substantial translational gap remains between the
The Challenges of Timely Prediction of Acute Kidney Injury
Critical illness is frequently linked with the deterioration of renal function [5]. The
kidneys possess a substantial functional reserve, enabling them to withstand the
decline in renal function despite exposure to various stressors. Therefore, significant
damage may have already occurred by the time a notable effect on serum creatinine
levels or u rinary output is observed [ 6 ]. Consequently, acute kidney injury (AKI)
presents a diagnostic and therapeutic challenge, with multiple definitions of acute
kidney damage emerging over time. According to the current KDIGO guidelines, the
diagnosis of AKI is based on an increase in serum creatinine beyond a specific
threshold relative to the patient’s baseline serum creatinine levels or a decrease in

29 Prediction and Machine Learning Models for Early Prediction of AKI 343
urinary output over time [7]. The assessment of the latter can be challenging in
hospitalized patients, owing to diuretic use and significant variations in patients’
fluid balance. Moreover, serum creatinine, as a functional marker, has its own
limitations for indicating acute kidney deterioration, as its elevation reflects damage
that has already occurred. Sepsis and AKI are intertwined syndromes, frequently
co-occurring in critical care settings. Recent reports indicate sepsis as a leading
of AKI, with AKI o ften complicating sepsis cases [5]. There exists a significant
opportunity for identifying AKI phenotypes within sepsis, especially considering
their evolution over time and potential therapeutic approaches [8]. The underlying
tissue damage in AKI is not solely attributable to ischemia and hypoperfusion
associated with a shock state but also to direct damage and disruption of metabolic
processes at the tubular and glomerular levels. This can happen in the context of
normal or even increased renal blood flow [
adaptive response of tubular renal cells to inflammatory mediators, characterized by
inflammation, microvascular dysfunction, and the trig gering of metabolic
downregulation and cell death in renal tubules [9–12]. Early detection is crucial
for timely intervention and possibly mitigating the progression of AKI. However, the
utility of these markers is constrained by variability across different tests and
limitations related to cost and availability [
a promising alternative by leveraging the extensive range of clinical, pharmacological, and vital data contained within electronic health records (EHRs), enabling rapid
assessment of renal function and deterioration.
9]. Sepsis-induced AKI is primarily an
13, 14]. Machine learning models offer
cause
Early Machine Learning Models for AKI Prediction
Machine learning algorithms have the capability to learn from hundreds of thousands
of clinical observations, discern patterns over time, and ultimately predict changes in
kidney function, including the onset of new kidney injuries or renal recovery. In a
seminal study by Flechet M. et al., published in 2017 [
machine learning model utilizing a random forest algorithm, with data derived from
the EPaNIC study [16]. The research produced four models, ranging from a baseline
model to a model evaluated 24 h after ICU admission. This study direc tly compared
the performance of the machine learning model with that of biomarkers, finding that
the ML model achieved comparable accuracy at a fraction of the cost. Additionally,
the model’s data were made available on a website, facilitating external use and
validation of the algorithm. This represents an immediate, practical application
potentially advantageous for resource-constrai ned settings.
Another study
analyzing electronic health record (EHR) data from a cohort of 121,158 patients at a
tertiary academic medical center [
including demographics, vital signs, diagnostics, and interventions, to predict the
onset of AKI Stage 2, utilizing a gradient boosting algorithm. Gradient boost ing is a
versatile machine learning technique applicable to a variety of tasks, including
focused on the risk prediction of acute kidney injury (AKI) by
17]. This model incorporated a range of data,
15], the authors introduced a

344 M. Greco et al.
regression and classification. The underlying principle of the algorithm involves an
iterative process: it starts by making predictions, identifies errors, and refines its
approach by focusing on these errors, thereby enhancing its ability to manage
complex cases. The algorithm’s ability to adapt to different optimization functions
and objectives offers the flexibility needed to address a broad spectrum of
scenarios [
18].
New Techniques for AKI Prediction Using Deep Learning ML Models
DeepMind, a leading AI research division of Google, unveiled an AKI predictive
model in 2019, utilizing a dataset comprising approximately 6 billion independent
entries, including 620,000 features. The dataset was divided into training (80%),
validation (5%), calibration (5%), and test (10%) sets. The model demonstrated the
capability to predict 55.8% of AKI cases up to 48 h in advance. Notably, its
predictive accuracy surged to over 90% for the most severe AKI cases [
future of AKI prediction using machine learning (ML) looks promising, with
significant advancements anticipated. A crucial factor will be the expanding volume
of data stored in electronic health records (EHRs), including genetic, metabolic, and
laboratory data, and more comprehensive integration of patient medical histories,
such as high-resolution data from previous hospital admissions. Another significant
development is the advancement of natural language processing (NLP) and its
application in medicine. Large language models (LLMs) have revolutionized information retrieval and text generation with remarkable accuracy. Some models are
now capable of incorporating clinical notes processed by NLP into predictive
models. For instance, a study focusing on AKI prediction in critically ill patients
utilized clinical notes from the first 24 h of ICU admission, sourced from the Medical
Information Mart for Intensive Care III (MIMIC-III) database. This approach
achieved an impressive area under the curve (AUC) of 0.779 by generating concept
representations of clinical notes through NLP, utilizing five supervised learning
classifiers and knowledge-guided deep learning algorithms [
real-time waveform data analysis, including arterial blood pressure, EKG, central
venous pressure, and respiratory data, opens new avenues for AKI prediction
21, 22]. Moreover, integrating real-time clinical data with genetic analysis will be
[
crucial in identifying sepsis patterns and sub-phenotypes, aiding in patient trajectory
delineation and therapeutic strategy development [23, 24]. Machine learning is
beginning to offer significant advantages over traditional methods in subphenotyping for sepsis and AKI, allowing for the identification of new patient
subgroups with distinct disease trajectories or responses to treatment within a
multidimensional data array, a task beyond human cognitive capabilities [25].
20].
19].
The
The advent of

29 Prediction and Machine Learning Models for Early Prediction of AKI 345
Clinical Decision Support Systems
A critical initial step in the effective implementation of machine learning
(ML) models in clinical practice is their integration into clinical decision support
systems (CDSS). CDSS are designed to provide timely alerts and suggestions to
clinicians, including information on drug-to-drug interactions and advice on potential trajectories of clinical deterioration that may otherwise be overlooked or recognized with delay in clinical practice [
smartphone applications, and notably, they can also be directly integrated into the
electronic health record (EHR) system. In a recent study published in The Lancet, the
authors demonstrated that integrating CDSS into clinical practice led to a reduction
in the number of potential adverse drug-drug interactions, resulting in a 12%
decrease in the administration of high-risk drug combinations to critically ill patients
within an ICU network in the Netherlands [28]. This suggests that CDSS are already
capable of positively influencing and enhancing clinical practice, and their interaction with clinicians may lead to favorable outcomes for patients.
26, 27]. CDSS can be accessed through web or
The Translational Research Gap and the Value of Data Sharing: A Plea for Data Sharing
In the domain of prescriptive modeling and clinical decision support systems
(CDSS), it is of pivotal importance to bridge the translation gap between the large
number of published models and their limited clinical applications. One of the key
limiting factors is the lack of external validity. This concept emphasizes the model’s
ability to maintain its performance when applied across different centers, thereby
enhancing the quality of care and patient outcomes and improving the healthcare
system. Consequently, models that may appear to work brilliantly in the center
where they were developed may fail spectacularly elsewhere. A critical factor
influencing the transferability of these models is the consistency of data collected
across different centers. Hospitals employ varying strategies and limitations in data
collection using electronic health record (EHR) systems. These differences encompass the types of data, spatial and temporal resolution, and specific variables
collected. Moreover, the nomenclature and clinical interpretation of the collected
data may vary widely across different centers. This discrepancy is reflected in the
differences in data structures employed by various EHR systems, further hindering
the shareability of models and CDSS. To overcome these limitations, standardization
of EHR data structures and the establishment of a common data dictionary across
countries and industries are necessary. This standardization could facilitate data
sharing and the diffusion of developed models in different healthcare settings,
ultimately improving patient care and outcomes.
Another crucial aspect to consider is the evolution of legal regulationsData
sharing, governed by the General Data Protection Regulation (GDPR) in Europe

346 M. Greco et al.
[29]. These regulations vary widely in other regions such as North America and Asia
and even across countries within the same region. According to GDPR, only
anonymized data can be freely exchanged. However, the practical implementation
of data anonymization presents a complex challenge akin to balancing an egg on its
end. True data anonymity is achievable only when all identifying information,
including dates, places, personal identifiers, images, specific comorbiditi
age, etc., are removed. Anonymization leads to a substantial loss of information
compared to the original data and presents researchers with an ethical tradeoff: on
one hand, there is a need to protect patient privacy regarding sensitive health data,
while on the other hand, the ability to use the model to enhance patient care depends
on the depth and details of the data. The scientific community must find a legal and
ethical compromise between these aspects to fac
clinical practice.
ilitate the diffusion of ML models in
es, precise
Limitations of Machine Learning Models
There are several different types of machine learning (ML) model s; however, most
share some common drawbacks. One problem, as mentioned earlier, is the lack of
external validity. ML models often exhibit moderate or low performance when
applied to different populations compared to their performance in the development
and testing cohort. This is attributed to the fact that their performance is dependent
on the quality of the data they are based upon, leading to the simple aphorism that an
ML model can only be as good as the underlying data on which it is built.
Moreover, deep learning models may exhibit good performance but are limited in
their interpretability. For example, in a study on retinal analysis, an ML model was
able to differentiate between male and female patients just from retinal photography,
a task which is impossible to perform by humans [
models may achieve high performance but remain “black-boxed,” encountering
barriers in their application in clinical practice, as no regulatory agency is willing
to approve a model that is fundamental ly a black box.
Another significant concern in the development of machine learning is the
potential amplification of biases and nonevidence-based practices inherent in the
original data [31]. Models trained on clinical data containing biases related to
traditional nonevidence-based practices may propagate bias, whereby preexisting
biases are learned and perpetuated by the model. This implies that gold standard
evidence from randomized controlled trials will continue to play a pivotal role in
addressing fundamental clinical research questions soon.
Data scientists and clinicians should invest efforts in preventing biases from
affecting model predictions to ensure that clinical decision support systems
(CDSS) can function equally and fairly across minorities and less privileged
sub-cohorts, ultimately resulting in better care for patients.
30]. Accordingly, deep learning
Соседние файлы в папке Библиотека им академика М.И. Перельмана
